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Summary
The respective contributions of pituitary and placental
GH to circulating IGF-I in pregnant women have not
been well established. We measured the serum con-
centrations of placental growth hormone (PGH) and
IGF-I in a woman with pit-1 de®ciency before, during
and after pregnancy, resulting in the birth of a healthy
child (not pit-1 de®cient). Both PGH and IGF-I con-
centrations were below the assay detection limit
before and after pregnancy. During pregnancy, PGH
and IGF-I levels increased steadily; the concentra-
tions of PGH and IGF-I in late pregnancy were com-
parable with levels previously measured in normal
pregnancies. PGH and IGF-I concentrations were
strongly correlated throughout pregnancy (r 0´90;
P 0´002). PGH was undetectable in cord serum,
whilst the IGF-I concentration was within the normal
range. The ®ndings of this case study corroborate the
notion that PGH is the prime regulator of maternal
serum IGF-I during pregnancy.
Introduction
Placental growth hormone (PGH) is encoded by the hGH-V
gene, which forms part of the hGH gene locus on chromosome
17 (q22 to q24), consisting also of the hGH-N gene and 3
chorionic somatomammotrophin (hCS-L, hCS-A and hCS-B)
genes. The hGH-N gene is expressed in the anterior pituitary,
whereas the hGH-V and the hCS genes are expressed in the
syncytiotrophoblast of the placenta.
PGH is secreted in a nonpulsatile manner. Whereas the
concentrations of PGH gradually increase during pregnancy,
pituitary GH concomitantly falls to undetectable levels. PGH is
thought to replace pituitary-derived GH during pregnancy; the
somatogenic activity of PGH appears to be mediated by the
production of IGF-I, similarly to pituitary-derived GH. Indeed,
the rise in PGH concentrations is correlated with that of IGF-I
in normal pregnancies, and both PGH and IGF-I levels fall
rapidly after delivery (Caufriez et al., 1990; Mirlesse et al.,
1993; Alsat et al., 1997).
Pituitary transcription factor 1 (pit-1) is a transcription factor
necessary for the expression of the hGH-N, the PRL and the
TSH genes in the pituitary (PfaÈf¯e et al., 1999), and for the
expression of the hGH-N but not the hGH-V gene in peripheral
blood mononuclear cells (Melen et al., 1997). Pit-1 messenger
RNA and protein have also been shown to be present in the
human placenta (Bamberger et al., 1995), and rat pit-1 has been
reported to bind to the distal site of the hGH-V gene (Nickel
et al., 1991). In this case study, we longitudinally measured
PGH and IGF-I concentrations in a pit-1 de®cient woman
before, during and after her second pregnancy.
Patient and methods
The woman concerned has been described previously (de
Zegher et al., 1995). Brie¯y, this Caucasian patient is
heterozygous for a point mutation in codon 271 of the pit-1
gene, with a C to T substition replacing an Arg (CTT) by a Trp
(TTT). GH was administered temporarily before the age of 19,
and ®nal height is 149´5 cm. The woman is also hypothyroid;
during her ®rst pregnancy, thyroid replacement therapy was
suboptimal, and mother and child (who was also pit-1 de®cient)
were found to be severely hypothyroid at delivery/birth (de
Zegher et al., 1995).
The 34-year-old patient was seen 7 and 2 months before her
second pregnancy, and at regular intervals during pregnancy.
Body weight increased from 61 kg before pregnancy (body
mass index: 27´3 kg/m2) to a maximum of 73´7 kg at 35 weeks.
The pregnancy was characterized by oedema and paresthesiae
in both hands from 12 weeks onwards, which improved
thereafter to worsen again from 35 weeks. Pedal oedema was
seen from 29 weeks onwards. Blood pressure was normal
throughout pregnancy. Based on circulating thyroid hormone
concentrations, L-T4 therapy was increased gradually from 75
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to 125 mg/day before conception (to attain high-normal free T4
levels in anticipation of pregnancy) and further to a maximum
of 150 mg/day during pregnancy. The patient agreed orally that
an additional blood tube be obtained for the purpose of this
study, each time blood was sampled to monitor L-T4 therapy.
There was no evidence of noncompliance with L-T4 therapy. At
15 weeks of pregnancy, the patient underwent an amniocent-
esis, and the molecular ®ndings indicated that the fetus was not
carrying the maternal pit-1 mutation. A healthy girl was born by
elective repeat caesarean section at 38´6 weeks, with birth
weight 3230 g (between 50th and 75th percentile, according to
the Flemish reference charts), length 49 cm and head circum-
ference 34 cm. Cord blood was sampled from the umbilical
artery after cord clamping. Because lactogenesis failed after the
®rst pregnancy (PRL levels were undetectable), breast feeding
was not attempted. The patient was seen 9 weeks after delivery,
and the L-T4 dose was lowered again.
PGH was measured using a two-site immunoradiometric
assay. Recombinant human PGH was used as the standard
(Igout et al., 1993), and monoclonal antibodies E8 and 7C12
were used in a 125I-labelled sandwich immunoassay (Igout &
Hennen, 1997). The molecular mass of PGH is 22 320 Da
(Igout et al., 1993). In this assay, the cross-reactivity of hGH,
hPRL and hPL is < 0´001% (Fig. 1). The intra-assay coef®cients
of variation were 5´1, 3´0 and 5´5%, for samples with PGH
concentrations of 20´5, 49´5 and 73´5 mg/l (low, medium and
high), respectively; the interassay coef®cients of variation were
5´5, 5´0 and 7´9%, respectively. The detection limit is about
0´2 mg/l (9 pmol/l) for serum samples. After acid ethanol
extraction, IGF-I was measured by radioimmunoassay using
recombinant human IGF-I (rhIGF-I) as the standard and a
polyclonal antiserum raised in guinea pigs, as described
previously (Verhaeghe et al., 1992, 1993). The detection limit
of the IGF-I assay is about 50 pg/tube, or 35 mg/l (4´6 nmol/l) for
routine serum samples.
Results and discussion
Figure 2 demonstrates that the serum concentrations of PGH
and IGF-I were undetectable and far below the detection limit,
respectively, in this pit-1 de®cient woman, both before (two
time points) and after pregnancy. For IGF-I, the results were 7
and 3 mg/l before pregnancy, and 1 mg/l after pregnancy (the
detection limit of routine assay is 35 mg/l); PGH was
undetectable in the three samples. There was a steady increase
in the levels of PGH and IGF-I in the course of pregnancy. The
maximum level of PGH was comparable with previous data in
normal pregnancies (Mirlesse et al., 1993). For IGF-I, the
maximum concentration was 53´7 nmol/l (411 mg/l), which is 3
SD above the mean previously measured with the same assay in
36 nonpregnant women of 30±40-year-old (31´3 6 7´6 nmol/l,
mean 6 SD) (Bouillon et al., 1995). Mirlesse et al. (1993)
reported that mean IGF-I levels rose from 20 to 26 nmol/l
(150±200 mg/l) in the ®rst half of pregnancy to 43´4 nmol/l
(332 mg/l) at term. Thus, the IGF-I concentrations in late
pregnancy in this patient are in line with previous ®ndings in
normal pregnancies; consequently, the rise in IGF-I levels
during early pregnancy was much steeper compared with
normal pregnancies. Interestingly, the patient developed
symptoms of oedema and paresthesiae in both hands at
12 weeks when IGF-I levels started to rise, and worsened at
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Fig. 1 Typical standard curve of the PGH two-site
immunoradiometric assay for serum samples, using recombinant
human PGH (A) as the standard, and monoclonal antibodies E8 and
7C12. There is no cross-reactivity in this assay with hGH (X), hPRL
(W) or hPL (B) (< 0´001%). Conversion to molar units: 10 mg/l










































Fig. 2 Serum PGH (A) and IGF-I (X) concentrations in a patient
with pit-1 de®ciency before, during and after pregnancy. PGH was
undetectable before and after pregnancy, while IGF-I concentrations
were far below the detection limit of the assay. During pregnancy,
there was a steep rise in both PGH and IGF-I concentrations, with a
strong correlation (r 0´90; P 0´002) between both parameters.
35 weeks when IGF-I values were maximal. Oedema and
paresthesiae (carpal tunnel-like symptoms) are known side-
effects of the use of rhIGF-I therapy (Jabri et al., 1994); rhIGF-I
has been shown to increase forearm blood ¯ow (Copeland &
Nair, 1994). PGH and IGF-I concentrations were strongly
correlated during pregnancy (r 0´90; P 0´002; n 8), a
®nding that con®rms the notion that PGH regulates maternal
serum IGF-I concentrations during pregnancy (Caufriez et al.,
1990; Mirlesse et al., 1993).
The IGF-I concentration in cord serum was 9´7 nmol/l,
which is within the normal range (mean 6 1 SD of 52 girls at
38 weeks: 8´4 6 3´0 nmol/l) (Verhaeghe et al., 1993). PGH
was undetectable in cord serum, con®rming previous data
(Frankenne et al., 1988).
In conclusion, serum PGH levels and IGF-I levels increased
steadily during pregnancy in a woman with pit-1 de®ciency,
and there was a strong correlation between both. This case
study shows that PGH is the prime regulator of maternal serum
IGF-I during pregnancy.
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